Abstract: The present disclosure provides an implantable device comprising a substrate capable of capturing an intraocular target molecule and to methods of use thereof.

Abstract: The present disclosure provides a microparticulate comprising one or more cannabinoids and a pH dependent release polymer. In embodiments, the one or more cannabinoids are present in an amount ranging from 10% w/w to about 50% w/w. In embodiments, the pH dependent release polymer is present in an amount ranging from ranging from about 5% w/w to about 85% w/w.

Abstract: Implantable materials visible under ultrasound may be delivered to a selected placement site and biodegrade after a certain period of time. Ultrasound visible implantable materials may be delivered through an applicator and may include ultrasound contrast agents and/or radiopaque agents. Applications include monitoring the delivery of an implant of the implantable materials to the placement site with ultrasound and delivery of therapeutic agents to a tissue at the placement site for treating a patient.

Abstract: Implantable materials visible under ultrasound may be delivered to a selected placement site and biodegrade after a certain period of time. Ultrasound visible implantable materials may be delivered through an applicator and may include ultrasound contrast agents and/or radiopaque agents. Applications include monitoring the delivery of an implant of the implantable materials to the placement site with ultrasound and delivery of therapeutic agents to a tissue at the placement site for treating a patient.

Abstract: One embodiment of the present invention is directed to compositions and methods for enhancing attachment of soft tissues to a metal prosthetic device. In one embodiment a construct is provided comprising a metal implant having a porous metal region, wherein said porous region exhibits a nano-textured surface.

Abstract: In various embodiments, the present invention provides methods of treating and/or preventing NASH and/or PBC comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Abstract: The invention relates to a soft chewable dosage form comprising a first active pharmaceutical ingredient encapsulated in a lipid material that is embedded in the soft chewable dosage form and wherein the soft chewable dosage form comprises at least a second active pharmaceutical ingredient as well as a method of treating a subject suffering from a disease or disorder in the gastro intestinal tract using the soft chewable dosage form.

Abstract: A depot system containing at least one antibiotic and a biodegradable poly(ester-anhydride) of ricinoleic acid (RA) and sebacic acid (SA) having alternating or semi-alternating ester and anhydride bonds is provided. The system provides prolonged local release of the antibiotic at the site of injection while maintaining the systemic antibiotic levels at sub-therapeutic concentrations.

Abstract: A nanomedicine for the treatment of obesity comprising either noble metal nanoparticles having surface ligands comprising a mixture comprising (+)-catechin (2R,3S) and gingerol or particles of a carbon nanomaterial having an adsorbed mixture comprising (+)-catechin (2R,3S) and gingerol. Also provided are a method for making the noble metal nanomedicine and the carbon nanomedicine. The nanomedicine is used in a method of treating obesity.

Abstract: This disclosure relates to nanoparticles comprising a core comprising a poly(ester amide) polymer comprising a repeating unit of Formula (Ia): and a repeating unit of Formula (Ib): wherein W1, W2, X1, A1, X2, A2, and X3 are as described herein, a payload molecule within the core, and a surface layer comprising a targeting ligand that binds or reacts selectively with a receptor on the outside surface of a cell. Methods of making such nanoparticles, and methods of using such nanoparticles as drug delivery vehicles, are also provided.

Abstract: A method of making infused bone fibers employs the following steps: cutting or shaving whole bone into bone fibers, washing the bone fibers, demineralizing or decalcifying at least partially the whole bone or bone fibers and infusing the bone fibers with a supernatant of biologic material or a polyampholyte cryoprotectant or a combination of both to create infused bone fibers. The step of infusing includes exposing the bone fibers to a negative pressure or vacuum to draw the supernatant and/or the polyampholyte cryoprotectant into the bone fibers, or alternatively, exposing the demineralized whole bone to a positive pressure to drive the supernatant and/or the polyampholyte cryoprotectant into the bone. The resultant method creates an infused bone grafting composition having bone fibers taken from whole bone, demineralized or decalcified at least partially and infused with one or more of a supernatant of biologic material or a polyampholyte cryoprotectant or both.

Abstract: Methods for preparing bone void filler substrates with carbonate surface coatings to promote bone growth.

Abstract: A method of making a nanocomposite includes forming at least one gold nanorod; coating a silver layer on an outer surface of the gold nanorod; assembling a Raman reporter molecule layer on the coated silver layer; coating a pegylated layer on the assembled Raman reporter molecule layer; and conjugating the coated pegylated layer with an active layer, the active layer comprising at least one of a targeting molecule configured to bind to the target of interest and a functional molecule configured to interact with the target of interest.

Abstract: This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides SE suppression and continued suppression of SE.

Abstract: Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided.

Abstract: The present specification discloses pharmaceutical compositions formulated as a suspension for oral administration, the suspension comprising solid particles of a non-steroidal anti-inflammatory drug (NSAID) in an oil carrier comprising one or more free fatty acids, a glycerolipid, and a phospholipid as well as methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: One drug (solid preparation) 100 of the present invention is a drug for a disease of kidney that contains a silicon fine particle, an aggregate of the silicon fine particles, or a crystal grain of silicon having a hydrogen-generating ability. Hydrogen generated from the silicon fine particle in the drug can contribute to the prevention and/or treatment of the kidney disease.

Abstract: A kit comprising a device for dosing and dispensing a dose of a non-liquid medicine that is readily dispersible in an aqueous solution suitable for oral administration, preferably a temozolomide formulation that can be titrated readily and accurately.

Abstract: Improved, stable aspirin formulations for intravenous use are disclosed. Methods of lyophilizing the aspirin from bulk solutions as well as kits containing the lyophilized aspirin and methods of treatment using the same are also disclosed.

Abstract: Disclosed is a personal care composition comprising: a) a porous particle; b) a film forming polymer; and c) a cosmetically acceptable carrier which is a water and oil emulsion; wherein the porous particle has oil absorption value in the range of 50 g/100 g to 1500 g/100 g; wherein the porous particle is selected from porous silica, cellulose, acrylic polymer, nylon and ethylene/methacylate copolymer hollow sphere coated with porous silica; wherein the film forming polymer is selected from an acrylate polymer, a methacrylate polymer, a urethane polymer or co-polymers thereof; and wherein the composition comprises whitening pigment in an amount of from 0.001 to 2 wt %.